Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

PEG interferon and ribavirin reduce liver fibrosis rate in hepatitis C

A combination of pegylated interferon and ribavirin significantly reduces the rate of fibrosis progression in patients with hepatitis C, according to research published in the May issue of Gastroenterology.

News image

fiogf49gjkf04

A group of international researchers evaluated the effect of pegylated (PEG) interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Individual data from 3010 naive patients, with pretreatment and post-treatment biopsies from 4 randomized trials, were pooled.

Ten different regimens combining standard interferon, PEG interferon, and ribavirin were compared.

The impact of each regimen was estimated by the percentage of patients with at least one grade improvement in the necrosis and inflammation (METAVIR score).

It was also assessed by the percentage of patients with at least one stage worsening in fibrosis METAVIR score, and by the fibrosis progression rate per year.

Necrosis and inflammation improvement ranged from 39% (interferon, 24 weeks) to 73% (optimized PEG interferon and ribavirin).

Fibrosis worsening ranged from 23% (interferon, 24 weeks) to 8% (optimized PEG interferon and ribavirin).

The team found that all regimens significantly reduced the fibrosis progression rates in comparison to rates before treatment.

Furthermore, the reversal of cirrhosis was observed in 49% of 153 patients with baseline cirrhosis.

Necrosis and inflammation improved by 73% with PEG interferon and ribavirin.
Gastroenterology

Six factors were found to be independently associated with the absence of significant fibrosis after treatment.

These included baseline fibrosis stage (odds ratio [OR] = 0.12), sustained viral response (OR = 0.36), and age less than 40 years (OR = 0.51).

The other associated factors were body mass index less than 27 kg/m2 (OR = 0.65), no or minimal baseline activity (OR = 0.70), and viral load less than 3.5 millions copies per milliliter (OR = 0.79).

Professor Thierry Poynard, of the University of Paris VI, Paris, France, concluded on behalf of the group, "PEG-interferon and ribavirin combination significantly reduces the rate of fibrosis progression in patients with hepatitis C."

In an accompanying Editorial, Professor Michael J.P. Arthur, of Southampton General Hospital, England, comments, "The study of Poynard et al. challenges all of us to accept that the traditional view of cirrhosis as a progressive, irreversible disease is no longer correct.

"This augurs well for the future of our patients with chronic HCV infection, particularly if they clear the virus with treatment," he adds.

"The study also encourages further scientific investigation of the key cell and molecular mechanisms of liver fibrosis.

"It raises the prospect that an antifibrotic agent, aimed at promoting regression of disease, may be an important therapeutic strategy for the future," he concludes.

Gastroenterology 2002; 122(5): 1303-13
03 May 2002

Go to top of page Email this page Email this page to a colleague

 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us